Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Huang, Kuo How ^a,b   Kuo, Kuan Lin ^b   Ho, I Lin ^b   Chang, Hong Chiang ^b   Chuang, Yuan Ting ^b   Lin, Wei Chou ^b   Lee, Ping Yi ^b   Chang, Shih Chen ^b,c   Chiang, Chih Kang ^b   Pu, Yeong Shiau ^b   Chou, Chien Tso ^b   Hsu, Chen Hsun ^b   Liu, Shing Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; AUTOPHAGY PROTEIN 5; BAFILOMYCIN A1; CELECOXIB; CYCLOOXYGENASE 2; GREEN FLUORESCENT PROTEIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL CULTURE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

ADENINE; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MACROLIDES; MAP KINASE KINASE 4; PHOSPHOPROTEINS; PYRAZOLES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; UBIQUITIN-ACTIVATING ENZYMES; URINARY BLADDER NEOPLASMS;

EID: 84891934329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082034     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Latini DM, Lerner SP, Wade SW, Lee DW, Quale DZ (2010) Bladder cancer detection, treatment and outcomes: opportunities and challenges. Urology 75: 334-339.
3. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, et al. (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3: 1463-1470. (Pubitemid 16246757)
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, et al. (1988) MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461-469. (Pubitemid 18082866)
5. Cohen MH, Rothmann M (2001) Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol 19: 1229-1231. (Pubitemid 32176302)
6. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077.
7. Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436. (Pubitemid 38050040)
8. Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW (2008) Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 7: 897-904. (Pubitemid 351551043)
9. Dovedi SJ, Kirby JA, Atkins H, Davies BR, Kelly JD (2005) Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmetteguerin immunotherapy for bladder cancer. J Urol 174: 332-337; discussion 337. (Pubitemid 40825752)
10. Han C, Leng J, Demetris AJ, Wu T (2004) Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64: 1369-1376. (Pubitemid 38235605)
11. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S (2004) Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67: 1469-1478. (Pubitemid 38388209)
12. Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, et al. (2006) Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15: 471-477.
13. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, et al. (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60: 5599-5602.
14. Qin J, Yuan J, Li L, Liu H, Qin R, et al. (2009) In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomed Pharmacother 63: 241-248.
15. Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, et al. (2008) OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res 68: 9348-9357.
16. Huang KH, Kuo KL, Chen SC, Weng TI, Chuang YT, et al. (2012) Downregulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PLoS One 7: e33615.
17. Huang S, Sinicrope FA (2010) Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 6: 256-269.
18. Jendrossek V, Handrick R, Belka C (2003) Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 17: 1547-1549.
19. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY (2004) Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96: 1769-1780. (Pubitemid 39654571)
20. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, et al. (2007) Calciumactivated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 6: 1262-1275. (Pubitemid 46711989)
21. Kroemer G, Marino G, Levine B (2010) Autophagy and the integrated stress response. Mol Cell 40: 280-293.
22. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, et al. (2007) Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res 67: 9677-9684. (Pubitemid 47621214)
23. Jin S, White E (2007) Role of autophagy in cancer: management of metabolic stress. Autophagy 3: 28-31. (Pubitemid 46100707)
24. Amaravadi RK, Thompson CB (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clinical cancer research : an official journal of the American Association for Cancer Research 13: 7271-7279.
25. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, et al. (2000) Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. Anticancer Res 20: 3221-3225.
26. Yu HJ, Tsai TC, Hsieh TS, Chiu TY (1992) Characterization of a newly established human bladder carcinoma cell line, NTUB1. J Formos Med Assoc 91: 608-613.
27. Huang AM, Kao YT, Toh S, Lin PY, Chou CH, et al. (2011) UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity. Biochem Pharmacol 82: 35-42.
28. Hour TC, Lai YL, Kuan CI, Chou CK, Wang JM, et al. (2010) Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells. Biochem Pharmacol 80: 325-334.
29. Cheng JH, Huang AM, Hour TC, Yang SC, Pu YS, et al. (2011) Antioxidant xanthone derivatives induce cell cycle arrest and apoptosis and enhance cell death induced by cisplatin in NTUB1 cells associated with ROS. Eur J Med Chem 46: 1222-1231.
30. Lin KW, Huang AM, Yang SC, Weng JR, Hour TC, et al. (2012) Cytotoxic and antioxidant constituents from Garcinia subelliptica. Food Chem 135: 851-859.
31. Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, et al. (2013) Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. Toxicol Lett 220: 267-276.
32. Lee PC, Kakadiya R, Su TL, Lee TC (2010) Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. Neoplasia 12: 376-387.
33. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, et al. (1973) Established cell line of urinary bladder carcinoma (T24) containing tumourspecific antigen. International journal of cancer Journal international du cancer 11: 765-773.
34. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42.
35. Suzuki SW, Onodera J, Ohsumi Y (2011) Starvation induced cell death in autophagy-defective yeast mutants is caused by mitochondria dysfunction. PLoS One 6: e17412.
36. Xia HG, Zhang L, Chen G, Zhang T, Liu J, et al. (2010) Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy 6: 61-66.
37. Hanada T, Ohsumi Y (2005) Structure-function relationship of Atg12, a ubiquitin-like modifier essential for autophagy. Autophagy 1: 110-118.
38. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. The EMBO journal 19: 5720-5728.
39. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, et al. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51-64.
40. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728.
41. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, et al. (2004) LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 117: 2805-2812. (Pubitemid 38997262)
42. Schonthal AH (2009) Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Lett 275: 163-169.
43. Seglen PO, Gordon PB (1982) 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A 79: 1889-1892. (Pubitemid 12088533)
44. Sakagami H, Kishino K, Amano O, Kanda Y, Kunii S, et al. (2009) Cell death induced by nutritional starvation in mouse macrophage-like RAW264.7 cells. Anticancer research 29: 343-347.
45. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585-595. (Pubitemid 38715985)
46. Yorimitsu T, Klionsky DJ (2005) Autophagy: molecular machinery for selfeating. Cell death and differentiation 12 Suppl 2: 1542-1552.
47. Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869. (Pubitemid 32267078)
48. Yorimitsu T, Klionsky DJ (2007) Endoplasmic reticulum stress: a new pathway to induce autophagy. Autophagy 3: 160-162. (Pubitemid 46449112)
49. Yorimitsu T, Nair U, Yang Z, Klionsky DJ (2006) Endoplasmic reticulum stress triggers autophagy. The Journal of biological chemistry 281: 30299-30304. (Pubitemid 44537037)
50. Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclooxygenase- 2 inhibitor. Clin Pharmacokinet 38: 225-242. (Pubitemid 30156623)
51. Menter DG, Schilsky RL, DuBois RN (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. ClinCancer Res 16: 1384-1390.
52. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, et al. (2000) Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 40: 124-132.
53. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, et al. (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60: 6045-6051.